Investigating a new treatment for opioid withdrawal symptoms.
Preclinical assessment of a Sterol Carrier Protein-2 inhibitor in multidimensional opioid withdrawal.
['FUNDING_R21'] · JOHNS HOPKINS UNIVERSITY · NIH-10671726
This study is looking at a new way to help people going through opioid withdrawal feel better by using a special treatment that could reduce symptoms like pain and anxiety without the side effects of regular cannabis products.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | JOHNS HOPKINS UNIVERSITY (nih funded) |
| Locations | 1 site (BALTIMORE, UNITED STATES) |
| Trial ID | NIH-10671726 on ClinicalTrials.gov |
What this research studies
This research focuses on improving the management of opioid withdrawal symptoms, which can be severe and multidimensional. It explores the use of a newly synthesized inhibitor that targets a specific protein involved in the transport of endocannabinoids, potentially increasing their levels in the body. By enhancing endocannabinoid tone, the research aims to alleviate symptoms such as pain, anxiety, and gastrointestinal distress without the adverse effects associated with traditional cannabinoid treatments. Patients may benefit from a more effective and safer approach to managing opioid withdrawal.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals experiencing opioid withdrawal symptoms or those with opioid use disorder.
Not a fit: Patients who are not currently undergoing opioid withdrawal or do not have opioid use disorder may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel treatment option that significantly reduces the discomfort associated with opioid withdrawal.
How similar studies have performed: Previous research has shown promise in using cannabinoid-related approaches for managing opioid withdrawal, indicating potential for success in this novel method.
Where this research is happening
BALTIMORE, UNITED STATES
- JOHNS HOPKINS UNIVERSITY — BALTIMORE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MOORE, CATHERINE FRANCES — JOHNS HOPKINS UNIVERSITY
- Study coordinator: MOORE, CATHERINE FRANCES
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.